Kiora Pharmaceuticals, Inc.

Equities

EYEG

US49721T5074

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 18:30:01 03/07/2024 BST			5-day change	1st Jan Change
4.32 ^USD	-2.70%		+8.00%	-8.12%

07-02	Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes	CI
06-25	Kiora Pharmaceuticals Appoints Roger A. Goldberg to its Scientific Advisory Board	CI

KIORA PHARMACEUTICALS INC : Other Events (form 8-K)

January 03, 2023 at 09:33 pm

Item 8.01 Other Events.

Effective as of January 1, 2023, Kiora Pharmaceuticals, Inc. (the "Company") moved its corporate headquarters to 332 Encinitas Boulevard, Suite 102, Encinitas, California 92024. The Company's telephone number remains the same: (781) 788-9043.

Latest news about Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes	07-02	CI
Kiora Pharmaceuticals Appoints Roger A. Goldberg to its Scientific Advisory Board	06-25	CI
Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M	05-10	MT
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating	02-09	MT
Kiora Pharmaceuticals Grants License to Thea Open for Molecular Photoswitch Product - Shares Surge	02-01	MT
Kiora Pharmaceuticals, Inc. announced that it expects to receive $42.274525 million in funding from ADAR1 Capital Management, LLC, Nantahala Capital Management, LLC, Rosalind Advisors, Inc., Stonepine Capital Management LLC, Velan Capital Partners LP	01-31	CI
Kiora Pharmaceuticals, Inc. Enters into an Exclusive License and Development Agreement with Théa Open Innovation SAS	01-31	CI
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
HC Wainwright Adjusts Kiora Pharmaceuticals' Price Target to $3.50 From $2, Keeps Buy Rating	11-06	MT
Kiora Pharmaceuticals, Inc. Announces Board Changes	21/09/23	CI
Certain Options of Kiora Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-SEP-2023.	31/08/23	CI
Certain Warrants of Kiora Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-SEP-2023.	31/08/23	CI
Certain Common Stock of Kiora Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-SEP-2023.	31/08/23	CI
HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $7, Keeps Buy Rating	14/08/23	MT
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director	01/08/23	CI
Kiora Pharmaceuticals, Inc. Enters into an Intellectual Property License Agreement with Sentrx Animal Care, Inc	15/06/23	CI
Sector Update: Health Care Stocks Rising Late Friday	02/06/23	MT
Sector Update: Health Care Stocks Rising Friday Afternoon	02/06/23	MT
Top Midday Decliners	02/06/23	MT
Kiora Pharmaceuticals Prices $5.5 Million Public Offering; Shares Drop	02/06/23	MT
Top Premarket Decliners	02/06/23	MT
HC Wainwright Raises Kiora Pharmaceuticals' Price Target to $7 From $6, Maintains Buy Rating	12/05/23	MT

Chart Kiora Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.32 USD

Average target price

33 USD

Spread / Average Target

+663.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KIORA PHARMACEUTICALS, INC.	-8.12%	13.19M
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	122B
REGENERON PHARMACEUTICALS, INC.	+16.60%	113B
ARGENX SE	+17.55%	26.22B
BIONTECH SE	-24.33%	19.01B
GENMAB A/S	-19.14%	15.71B
BEIGENE, LTD.	-17.95%	15.22B
WUXI APPTEC CO., LTD.	-46.81%	14.72B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.58B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.84B

Bio Therapeutic Drugs